Efficacy of Pregabalin on Chronic Cough

• Status: Recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if Pregabalin, a medication used for the treatment of seizures and chronic pain, can be used to effectively treat people who suffer from non-asthmatic chronic cough (cough lasting over 8 weeks).

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ottawa Hospital Research Institute
• Treatments: Pregabalin

Criteria

Inclusion Criteria:

• Diagnosis of non-asthmatic chronic cough defined as a cough experienced for a period of at least 8 weeks

• Negative methacholine challenge (within past year)

• Chest x-ray with absence of gross abnormality that could justify the cough or be a cause for the cough (within past 6 months)

• Male or female 18 years or older

• Willing and able to limit to 1 or less alcohol beverage per day (example: 360 ml of beer or 330 ml of cooler or 120 ml of wine)

Exclusion Criteria:

• Concurrent use of Gabapentin or Pregabalin for other indications (seizure disorder, chronic pain)

• History of allergy / intolerance or adverse effect with Gabapentin or Pregabalin.

• Concurrent use of central nervous system depressants (i.e. opioids or benzodiazepines)

• Not able to limit daily alcohol intake as recommended in the inclusion criteria

• Creatinine clearance < 60ml/min within past three months

• Current Smoker or has been quit less than 8 weeks

• Symptoms of post nasal drip

• History of gastroesophageal reflux. Only participants with untreated Gastroesophageal Reflux Disease (GERD) or less than 8 weeks of therapy will be excluded.

• Symptoms of upper airway cough syndrome

• ACE inhibitor use

• Allergy to citric acid

• Pregnant or nursing women

• History of angioedema or congestive heart failure